IMR Press / EJGO / Volume 22 / Issue 3 / pii/2001143

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced Fallopian tube carcinoma

Show Less
1 Department of Gynecology, Leiden University Medical Center, Leiden, The Netherlands
2 EORTC Data Center, Brussels, Belgium
3 Department of Gynecology, Universita di Brescia, Italy
4 Department of Gynecologic Oncology, University Hospitals Leuven, Belgium
5 Department of Medical Oncology, St. Radboud Academic Hospital, Nijmegen, The Netherlands
6 Department of Oncology, Medical University of Gdansk, Poland
7 Department of Gynecology, lnstituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
8 Department of Oncology, Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands
9 Department of Oncology, Hospital General de Asturias, Oviedo, Spain
10 Department of Oncology, lnstitut d' Oncologia Corachan, Barcelona, Spain
11 Department of Oncology, Hospital Cantonal Universitaire de Geneve, Switzerland
12 Department of Gynecology, Hospitais da Universidade de Coimbra, Portugal
13 Department of Obstetrics and Gynecology, Ospedale San Gerardo, Monza, Italy
14 Department of Oncology, Leiden University Medical Center, Leiden, The Netherlands
15 Department of Oncology, Centre Rene Huguenin, Saint-Cloud, France
16 Department of Internal Medicine, Centre Eugene Marquis, Rennes, France
17 Department of Gynecology, Innsbruck Universitaetsklinik, Innsbruck, Austria
18 Department of Oncology, Azienda Ospedaliera Santa Maria Degli Angeli, Pordenone, Italy
19 Department of Oncology, Azienda Ospedaliera Santa Maria Degli Angeli, Pordenone, Italy
20 Department of Oncology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
21 Department of Oncology, University Hospital Antwerp, Edegem, Belgium
Eur. J. Gynaecol. Oncol. 2001, 22(3), 187–193;
Published: 10 June 2001

Objective: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. Methods: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 admi­nistered intravenously on day one every 28 days. Results: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. Conclusion: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.

Fallopian tube carcinoma
Phase II trial
Back to top